Drugs / BAT6026
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05109650 | Feb 2022 → Mar 2023 | — | Bio-Thera Solutions | Terminated | No outcome recorded |
| Phase 1 | NCT05105971 | Dec 2021 → Nov 2023 | cancer | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06094179 | Nov 2023 → Jun 2026 overdue | atopic eczema | Bio-Thera Solutions | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT6026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06094179 ↗ |
| Modality | Monoclonal antibody | “anti-OX40 monoclonal antibody” NCT05105971 ↗ |
| Route | Intravenous | “BAT6026 0.01mg/kg,intervenous infusion” NCT05105971 ↗ |